TipRanks
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
US Market
JAZZ
Jazz Pharmaceuticals
RESEARCH TOOLSreports
Want to see JAZZ full AI Analyst Report?

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

1,940 Followers
See the Price Targets and Ratings of:

JAZZ Analyst Ratings

Strong Buy
18Ratings
Strong Buy
17 Buy
1 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Jazz
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JAZZ Stock 12 Month Forecast

Average Price Target

$298.17
▲(14.58% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $298.17 with a high forecast of $337.00 and a low forecast of $229.00. The average price target represents a 14.58% change from the last price of $260.23.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"135":"$135","338":"$338","185.75":"$185.8","236.5":"$236.5","287.25":"$287.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":337,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$337.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":298.1666666666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$298.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":229,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$229.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[135,185.75,236.5,287.25,338],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,233.01,241.00923076923075,249.00846153846152,257.0076923076923,265.00692307692304,273.00615384615384,281.0053846153846,289.00461538461536,297.00384615384615,305.00307692307695,313.0023076923077,321.0015384615385,329.0007692307692,{"y":337,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,233.01,238.02205128205128,243.03410256410257,248.04615384615386,253.05820512820512,258.07025641025643,263.0823076923077,268.094358974359,273.10641025641024,278.11846153846153,283.1305128205128,288.1425641025641,293.1546153846154,{"y":298.1666666666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,233.01,232.70153846153846,232.3930769230769,232.08461538461538,231.77615384615385,231.4676923076923,231.15923076923076,230.85076923076923,230.5423076923077,230.23384615384614,229.92538461538462,229.6169230769231,229.30846153846153,{"y":229,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":136.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.29,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.27,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.72,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":232.64,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237.51,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.86,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.71,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":233.01,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$337.00Average Price Target$298.17Lowest Price Target$229.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on JAZZ
Ami Fadia
Needham
Needham
$310
Buy
19.13%
Upside
Reiterated
10/16/26
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Jade Biosciences (JBIO)
Citi Analyst forecast on JAZZ
Geoff Meacham
Citi
Citi
$325
Buy
24.89%
Upside
Reiterated
10/15/26
Citi Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Barclays Analyst forecast on JAZZ
Etzer Darout
Barclays
Barclays
$271
Buy
4.14%
Upside
Reiterated
10/13/26
Barclays Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Bank of America Securities Analyst forecast on JAZZ
Jason Gerberry
Bank of America Securities
Bank of America Securities
$307→$313
Buy
20.28%
Upside
Reiterated
10/09/26
Jazz Pharmaceuticals price target raised to $313 from $307 at BofAJazz Pharmaceuticals price target raised to $313 from $307 at BofA
RBC Capital Analyst forecast on JAZZ
Leonid Timashev
RBC Capital
RBC Capital
$299→$296
Buy
13.75%
Upside
Reiterated
10/08/26
Jazz Pharmaceuticals price target lowered to $296 from $299 at RBC CapitalJazz Pharmaceuticals price target lowered to $296 from $299 at RBC Capital
Truist Financial Analyst forecast on JAZZ
Gregory Renza
Truist Financial
Truist Financial
$281→$286
Buy
9.90%
Upside
Reiterated
10/07/26
Jazz Pharmaceuticals price target raised to $286 from $281 at TruistJazz Pharmaceuticals price target raised to $286 from $281 at Truist
Piper Sandler Analyst forecast on JAZZ
David Amsellem
Piper Sandler
Piper Sandler
$310
Buy
19.13%
Upside
Reiterated
09/28/26
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Ocugen (OCGN)
Bernstein Analyst forecast on JAZZ
Jeffrey Walch
Bernstein
Bernstein
$229
Hold
-12.00%
Downside
Reiterated
09/25/26
Bernstein Reaffirms Their Hold Rating on Jazz Pharmaceuticals (JAZZ)
Goldman Sachs Analyst forecast on JAZZ
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$337
Buy
29.50%
Upside
Initiated
09/24/26
Goldman Sachs Resumes Coverage with a Buy Rating on Jazz Pharmaceuticals (JAZZ)
UBS Analyst forecast on JAZZ
Ashwani Verma
UBS
UBS
$315→$337
Buy
29.50%
Upside
Assigned
09/14/26
Jazz Pharmaceuticals price target raised to $337 from $315 at UBSJazz Pharmaceuticals price target raised to $337 from $315 at UBS
TD Cowen Analyst forecast on JAZZ
Joseph Thome
TD Cowen
TD Cowen
$300
Buy
15.28%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Jazz Pharmaceuticals (JAZZ)
Canaccord Genuity Analyst forecast on JAZZ
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$300
Buy
15.28%
Upside
Reiterated
08/31/26
Jazz Pharmaceuticals: Ziihera’s Strong 1L GEA Profile Supports Reiterated Buy Rating and Unchanged $300 Price Target
Morgan Stanley Analyst forecast on JAZZ
Sean Laaman
Morgan Stanley
Morgan Stanley
$283→$322
Buy
23.74%
Upside
Assigned
08/26/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), Amneal Pharmaceuticals (NASDAQ: AMRX) and Climb Bio (NASDAQ: CLYM)
Deutsche Bank Analyst forecast on JAZZ
David Hoang
Deutsche Bank
Deutsche Bank
$287→$300
Buy
15.28%
Upside
Reiterated
08/26/26
Jazz Pharmaceuticals price target raised to $300 from $287 at Deutsche BankJazz Pharmaceuticals price target raised to $300 from $287 at Deutsche Bank
Wells Fargo Analyst forecast on JAZZ
Mohit Bansal
Wells Fargo
Wells Fargo
$300
Buy
15.28%
Upside
Reiterated
08/10/26
Wells Fargo Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on JAZZ
Ami Fadia
Needham
Needham
$310
Buy
19.13%
Upside
Reiterated
10/16/26
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Jade Biosciences (JBIO)
Citi Analyst forecast on JAZZ
Geoff Meacham
Citi
Citi
$325
Buy
24.89%
Upside
Reiterated
10/15/26
Citi Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Barclays Analyst forecast on JAZZ
Etzer Darout
Barclays
Barclays
$271
Buy
4.14%
Upside
Reiterated
10/13/26
Barclays Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Bank of America Securities Analyst forecast on JAZZ
Jason Gerberry
Bank of America Securities
Bank of America Securities
$307→$313
Buy
20.28%
Upside
Reiterated
10/09/26
Jazz Pharmaceuticals price target raised to $313 from $307 at BofAJazz Pharmaceuticals price target raised to $313 from $307 at BofA
RBC Capital Analyst forecast on JAZZ
Leonid Timashev
RBC Capital
RBC Capital
$299→$296
Buy
13.75%
Upside
Reiterated
10/08/26
Jazz Pharmaceuticals price target lowered to $296 from $299 at RBC CapitalJazz Pharmaceuticals price target lowered to $296 from $299 at RBC Capital
Truist Financial Analyst forecast on JAZZ
Gregory Renza
Truist Financial
Truist Financial
$281→$286
Buy
9.90%
Upside
Reiterated
10/07/26
Jazz Pharmaceuticals price target raised to $286 from $281 at TruistJazz Pharmaceuticals price target raised to $286 from $281 at Truist
Piper Sandler Analyst forecast on JAZZ
David Amsellem
Piper Sandler
Piper Sandler
$310
Buy
19.13%
Upside
Reiterated
09/28/26
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Ocugen (OCGN)
Bernstein Analyst forecast on JAZZ
Jeffrey Walch
Bernstein
Bernstein
$229
Hold
-12.00%
Downside
Reiterated
09/25/26
Bernstein Reaffirms Their Hold Rating on Jazz Pharmaceuticals (JAZZ)
Goldman Sachs Analyst forecast on JAZZ
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$337
Buy
29.50%
Upside
Initiated
09/24/26
Goldman Sachs Resumes Coverage with a Buy Rating on Jazz Pharmaceuticals (JAZZ)
UBS Analyst forecast on JAZZ
Ashwani Verma
UBS
UBS
$315→$337
Buy
29.50%
Upside
Assigned
09/14/26
Jazz Pharmaceuticals price target raised to $337 from $315 at UBSJazz Pharmaceuticals price target raised to $337 from $315 at UBS
TD Cowen Analyst forecast on JAZZ
Joseph Thome
TD Cowen
TD Cowen
$300
Buy
15.28%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Jazz Pharmaceuticals (JAZZ)
Canaccord Genuity Analyst forecast on JAZZ
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$300
Buy
15.28%
Upside
Reiterated
08/31/26
Jazz Pharmaceuticals: Ziihera’s Strong 1L GEA Profile Supports Reiterated Buy Rating and Unchanged $300 Price Target
Morgan Stanley Analyst forecast on JAZZ
Sean Laaman
Morgan Stanley
Morgan Stanley
$283→$322
Buy
23.74%
Upside
Assigned
08/26/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), Amneal Pharmaceuticals (NASDAQ: AMRX) and Climb Bio (NASDAQ: CLYM)
Deutsche Bank Analyst forecast on JAZZ
David Hoang
Deutsche Bank
Deutsche Bank
$287→$300
Buy
15.28%
Upside
Reiterated
08/26/26
Jazz Pharmaceuticals price target raised to $300 from $287 at Deutsche BankJazz Pharmaceuticals price target raised to $300 from $287 at Deutsche Bank
Wells Fargo Analyst forecast on JAZZ
Mohit Bansal
Wells Fargo
Wells Fargo
$300
Buy
15.28%
Upside
Reiterated
08/10/26
Wells Fargo Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jazz Pharmaceuticals

3 Months
Joseph ThomeTD Cowen
Success Rate
13/21 ratings generated profit
62%
Average Return
+6.27%
Copying Joseph Thome's trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +6.27% per trade.
1 Year
Joseph ThomeTD Cowen
Success Rate
17/21 ratings generated profit
81%
Average Return
+33.96%
Copying Joseph Thome's trades and holding each position for 1 Year would result in 80.95% of your transactions generating a profit, with an average return of +33.96% per trade.
2 Years
Joseph ThomeTD Cowen
Success Rate
18/21 ratings generated profit
86%
Average Return
+53.33%
Copying Joseph Thome's trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +53.33% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JAZZ Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
1
Buy
31
35
54
50
46
Hold
4
4
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
39
56
51
48
In the current month, JAZZ has received 47 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. JAZZ average Analyst price target in the past 3 months is 298.17.
Each month's total comprises the sum of three months' worth of ratings.

JAZZ Financial Forecast

JAZZ Earnings Forecast

Next quarter’s earnings estimate for JAZZ is $6.28 with a range of $5.74 to $6.95. The previous quarter’s EPS was $5.71. JAZZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.
Next quarter’s earnings estimate for JAZZ is $6.28 with a range of $5.74 to $6.95. The previous quarter’s EPS was $5.71. JAZZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.

JAZZ Sales Forecast

Next quarter’s sales forecast for JAZZ is $1.21B with a range of $1.17B to $1.24B. The previous quarter’s sales results were $1.21B. JAZZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.
Next quarter’s sales forecast for JAZZ is $1.21B with a range of $1.17B to $1.24B. The previous quarter’s sales results were $1.21B. JAZZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.

JAZZ Stock Forecast FAQ

What is JAZZ’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is 298.17.
    What is JAZZ’s upside potential, based on the analysts’ average price target?
    Jazz Pharmaceuticals has 14.58% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is JAZZ a Buy, Sell or Hold?
          Jazz Pharmaceuticals has a consensus rating of Strong Buy which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Jazz Pharmaceuticals’s price target?
            The average price target for Jazz Pharmaceuticals is 298.17. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $337.00 ,the lowest forecast is $229.00. The average price target represents 14.58% Increase from the current price of $260.23.
              What do analysts say about Jazz Pharmaceuticals?
              Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of JAZZ?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.